Talotrexin clinical trials
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2003
How each study uses talotrexin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2003 (1)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
Spectrum Pharmaceuticals, Inc (3) · Dana-Farber Cancer Institute (1) · Children's Oncology Group (1)
Related medicines
As reviewed, each with the page that says it.
- One of Antimetabolites source
Studies
Open first, then newest update. How each study uses talotrexin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Talotrexin in Treating Patients With Advanced or Recurrent Solid TumorsCompletedPhase 1Dana-Farber Cancer InstituteNCT00098514Written as talotrexin ammoniumHow we know
- Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to TreatmentWithdrawnPhase 1Children's Oncology GroupNCT00458744Written as talotrexinHow we know
- Safety Study of PT-523 in Cancer Patients to Treat Solid Tumors Including a Preliminary Assessment of EffectivenessTerminatedPhase 1Spectrum Pharmaceuticals, IncNCT00088023Written as PT-523 for InjectionHow we know
- A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)WithdrawnPhase 1/2Spectrum Pharmaceuticals, IncNCT00112060Written as PT-523 for InjectionHow we know
- A Study to Evaluate PT-523 in Patients With Refractory LeukemiaWithdrawnPhase 1/2Spectrum Pharmaceuticals, IncNCT00129558Written as PT-523 for InjectionHow we know
Codes
What other systems call talotrexin · ClinicalTrials.gg INT003771
- UNII (FDA) A8E516A20KTALOTREXINConfirmed FDA, NLM, Wikidata
- Wikidata Q27273768talotrexinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C29341TalotrexinOne source FDA
- DrugBank DB06178One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | A8E516A20K | TALOTREXIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27273768 | talotrexin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C29341 | Talotrexin | One source FDA |
| DrugBank | DB06178 | — | One source Wikidata |
Also registered as talotrexin ammonium (UNII 686WJT9102).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.